Abselion

Abselion's primary product is the Amperia system, a compact, benchtop instrument that provides automated, at-line quantification of proteins and viral vectors directly from unpurified samples. This system is built on proprietary Redox Electrochemical Detection (RED) technology, which tracks electrical changes as molecules interact, offering high sensitivity and specificity without the need for complex optics or fluidics. The Amperia system can deliver measurement results in as little as one minute per sample, significantly speeding up access to critical data for bioprocess optimization and decision-making. This allows researchers to monitor processes like cell line development and viral vector manufacturing in near real-time.

The company generates revenue through the sale of its Amperia instrument and the accompanying RED-Sensors and reagent kits required for various assays, such as monoclonal antibody and AAV quantification. In December 2024, Abselion secured £6.6 million in a Series A funding round led by M Ventures, the corporate venture arm of Merck. This funding is aimed at driving the commercialization and expansion of the Amperia system's capabilities. Key investors include BGF, R42, BioProcess 360 Partners, and Untitled Ventures.